

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

| <b>Research and Professional Experience:</b>  |                            |
|---|----------------------------|
| MOORE Clinical Research, Inc, Clinical Investigator   | December 2018-Present      |
| Clear Path Center, Staff Physician  | January 2017-February 2017 |
| Kenaday Medical, Medical Director   | July 2015-January 2017     |
| First Coast Pain Management, Medical Director   | October 2014-May 2015      |
| Affordable Healthcare, Medical Director   | January 2014-October 2014  |
| Kenaday Medical Clinic, Staff Physician   | June 2013-December 2014    |
| Samaritan Occupational Medicine Department, Chief Physician                                   | January 2005-May 2013      |
| Samaritan Urgent Care, Chief Physician  | October 2002-January 2005  |
| Veterans' Health Administration, Physician, PM&R Locums                                       | September 2001-Nov. 2001   |
| Concord NH. Solo Practice, Staff Physician  | September 1999-August 2001 |
| Concord Orthopedics, Staff Physician  | July 1996-August 1999      |
| Dept of Physical Medicine & Rehabilitation Tufts, Resident                                    | July 1993-June 1996        |
| Back Clinic Tufts Dept. of PM&R, Physician, Locums  | March 1993-June 1993       |
| Virginia Mason Clinic, Occupational Medicine Physician  | August 1992-January 1993   |
| Providence Hospital Occupational Medicine Clinic, Staff Physician                             | July 1991-December 1993    |
| Back in Action Clinic, Medical Director   | July 1991-August 1992      |
| Evergreen Surgery Center, Orthopedic Surgery Assistant  | December 1990-August 1991  |
| Med Idea Inc., CEO, Medical Director  | August 1987-June 1991      |
| MedAlaska Inc, CEO, Physician   | February 1981-August 1987  |
| Solo Family Practice, Assisting Surgeon   | Dec. 1978-Dec. 1981        |
| Kaiser Medical Center, Emergency Medicine, Chief Surgeon                                      | July 1975-December 1978    |
| Madigan Medical Center, Emergency Physician   | July 1974-June 1975        |
| United States Army, 25 <sup>th</sup> Infantry, General Medical Officer, First Brigade Surgeon | July 1972-June 1974        |

| <b>Education and Postdoctoral Training:</b>  |           |
|--|-----------|
| Residency, Physical Medicine and Rehabilitation, Tufts School of Medicine, Boston MA | June 1996 |
| Doctor of Medicine, University of Washington School of Medicine, Seattle, WA         | June 1971 |
| Experimental Pathology, University of Washington School of Medicine, Seattle, WA     | June 1967 |
| Bachelors in Zoology, University of Washington School of Medicine, Seattle, WA       | June 1965 |
| Associates Degree in Art, Everett Community College, Everett, WA                     | June 1963 |

| <b>Licenses/Certifications/Memberships:</b>                                |               |
|--|---------------|
| State of Florida Medical License ME 116322, DEA FM7947596                  | January 2021  |
| Board Certified, American Board of Family Medicine                         | April 2017    |
| Bloodborne Pathogens & Biomedical Waste Management 29 CFR OSHA Regulations | December 2018 |
| BLS for Healthcare Providers, American Heart Association                   | May 2019      |
| ACLS for Healthcare Providers, American Heart Association                  | June 2019     |

| <b>Training:</b>  |              |
|---|--------------|
| Adverse Event Collection and Reporting in Clinical Research | January 2019 |
| Bloodborne Pathogens & Biomedical Waste Management          | January 2019 |

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

|   |              |
|---|--------------|
| Comprehensive SOP Review                      | January 2019 |
| Responsible Conduct of Research, CITI Program | January 2019 |
| Good Clinical Practice, NIH Training          | January 2019 |
| Human Subject Assurance Training              | January 2019 |

Signature

Date

**Clinical Trial Experience:**

- ACNE VULGARIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Lotion 1% (XXXX) to Clindamycin Phosphate Topical Lotion 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone® (Dapsone) Gel, 7.5% (XXXX) and Both Active Treatments to A Placebo Control in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle Controlled Study of XXXX in the Treatment of Acne Vulgaris." 2019, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Gel 1% (XXXX) to Cleocin T (Clindamycin Phosphate Topical Gel 1%, XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019, Principal Investigator

"A Phase 2, Randomized, Multicenter, Double-Blind, Vehicle Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Daily for 12 Weeks in Subjects with Facial Acne Vulgaris for Treatment of Moderate to Severe Inflammatory Acne Vulgaris" 2019, Sub-Investigator

- ATOPIC DERMATITIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Doxepin Hydrochloride Topical Cream, 5% (XXXX) to Doxepin Hydrochloride topical cream, 5% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Pruritis in Adults with Atopic Dermatitis." 2019 Sub-Investigator

- ACTINIC KERATOSIS

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Bioequivalence Study to Compare XXXX 5-FU Cream 5%, with Efudex (5-FU) Cream 5%, and Both Active Treatments to a Vehicle Control, in the Treatment of Actinic Keratosis." 2019, Sub-Investigator

- PSORIASIS

"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of XXXXX in Subjects with Moderate-to-Severe Plaque Psoriasis." 2018, Sub-Investigator

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

"A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-Severe Plaque Psoriasis.: 2018, Sub-Investigator

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriol and Betamethasone Dipropionate Topical Gel 0.005%/0.064% (XXXX) Dovobet® Gel (Calcipotriol and Betamethasone Dipropionate Gel) 0.005%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Mild to Moderate Body Plaque Psoriasis Vulgaris." 2018 Sub-Investigator

- SCALP PSORIASIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% (XXXX) to Talconex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical Suspension 0.005%.0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis." 2018, Sub-Investigator

- TINEA PEDIS

"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutics Equivalence of Ketoconazole Cream 2% (XXXX) to Ketoconazole 2% (XXXX) in the Treatment of Tinea Pedis." 2019, Principal Investigator

- INFLUENZA

"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza." 2018, Sub-Investigator